Education
About Us
Working with TipRanks
Follow Us
Monogram Orthopaedics Inc (MGRM)
NASDAQ:MGRM
RESEARCH TOOLSreports
Top Page
Monogram Orthopaedics Inc
(NASDAQ:MGRM)
53Neutral
Monogram Orthopaedics Inc (MGRM) vs. S&P 500 (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)1.28M
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue Growth-100.00%
EPS Growth8.75%
CountryUS
Employees27
SectorHealthcare
Sector Strength72
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.51
Shares Outstanding35,289,444
10 Day Avg. Volume3,751,148
30 Day Avg. Volume1,278,918
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)307.45
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.40Price Target Upside93.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Monogram Orthopaedics Inc Business Overview & Revenue Model
Company DescriptionMonogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
How the Company Makes MoneyMonogram Orthopaedics Inc generates revenue primarily through the sale of its orthopedic implants and associated surgical systems. The company's revenue model is based on direct sales to healthcare providers, hospitals, and surgical centers. Additionally, Monogram may engage in partnerships with other medical device companies to expand its market reach and enhance its product offerings. Revenue can also be derived from licensing its proprietary technology to other entities in the medical field. The company's earnings are influenced by its ability to innovate and bring cutting-edge solutions to market, as well as its capacity to establish relationships with key stakeholders in the healthcare industry.
Monogram Orthopaedics Inc Financial Statement Overview
Summary
Monogram Orthopaedics Inc. faces significant financial challenges, primarily due to its inability to generate revenue and achieve profitability. The balance sheet indicates manageable debt levels, but cash flow constraints highlight operational inefficiencies. Improvement in revenue generation and operational optimization is necessary to enhance financial standing.Income Statement
Monogram Orthopaedics Inc. has consistently struggled with generating revenue, with $0 revenue reported in 2024. Despite a brief increase in 2021, the revenue trend remains negative. Gross profit margins remain non-existent, and the company continues to operate at a loss, as evidenced by negative EBIT and net income. These factors highlight significant challenges in scaling operations and achieving profitability.25
Negative
Balance Sheet
The company maintains a reasonable debt-to-equity ratio, thanks to low levels of debt and a positive equity base. However, the equity ratio indicates limited asset backing. While liabilities are relatively small, the company must improve its equity position to strengthen financial stability. The balance sheet suggests a need for strategic asset growth to enhance financial health.45
Neutral
Cash Flow
Operating cash flow has been persistently negative, indicating cash flow challenges in daily operations. Although financing activities have bolstered cash reserves, the lack of free cash flow growth poses concerns. The reliance on financing for cash flow sustainability is a potential risk factor, emphasizing the need for improved operational efficiency.30
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 365.00K | 0.00 | 365.00K | 0.00 | 628.25K | 0.00 | Gross Profit |
| 47.21K | 0.00 | 365.00K | -386.69K | 169.57K | -95.69K | EBIT |
| -16.27M | -15.31M | -17.27M | -10.61M | -10.28M | -6.85M | EBITDA |
| -15.84M | -15.31M | -16.86M | -10.23M | -9.96M | -6.76M | Net Income Common Stockholders |
| -15.73M | -16.33M | -13.75M | -13.69M | -11.81M | -9.07M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.32M | 15.66M | 13.59M | 10.47M | 5.54M | 5.59M | Total Assets |
| 2.62M | 17.77M | 16.58M | 13.69M | 8.72M | 8.12M | Total Debt |
| 2.12M | 364.00K | 491.99K | 610.15K | 211.46K | 205.49K | Net Debt |
| -195.39K | -15.29M | -13.10M | -9.86M | -5.32M | -5.38M | Total Liabilities |
| 2.89M | 3.27M | 3.18M | 9.54M | 5.21M | 3.13M | Stockholders Equity |
| -274.63K | 14.50M | 13.40M | 4.15M | 3.50M | 4.99M |
| Cash Flow | Free Cash Flow | ||||
| -14.15M | 0.00 | -13.61M | -8.66M | -10.17M | -6.74M | Operating Cash Flow |
| -14.08M | 0.00 | -13.54M | -8.42M | -9.17M | -5.40M | Investing Cash Flow |
| -71.96K | -84.00K | -64.91K | -241.20K | -1.01M | -1.33M | Financing Cash Flow |
| 15.84M | 16.12M | 16.73M | 13.59M | 10.12M | 10.01M |
Monogram Orthopaedics Inc Technical Analysis
Positive
2.79
Price Trends
2.67
Positive
2.51
Positive
2.50
Positive
Market Momentum
0.13
Negative
50.57
Neutral
17.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGRM, the sentiment is Positive. The current price of 2.79 is above the 20-day moving average (MA) of 2.73, above the 50-day MA of 2.67, and above the 200-day MA of 2.50, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 17.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGRM.
Monogram Orthopaedics Inc Risk Analysis
Monogram Orthopaedics Inc disclosed 52 risk factors in its most recent earnings report. Monogram Orthopaedics Inc reported the most risks in the “Production” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monogram Orthopaedics Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $22.35B | 25.33 | 7.24% | 0.85% | 3.84% | -9.29% | |
69 Neutral | $4.68B | 90.71 | 8.48% | ― | 28.49% | ― | |
53 Neutral | ― | -117.05% | ― | -100.00% | 8.75% | ||
50 Neutral | $49.13M | ― | -114.70% | ― | -8.11% | -23.04% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
46 Neutral | $1.28B | ― | -291.71% | ― | 26.81% | 26.47% | |
43 Neutral | $440.33M | ― | -166.29% | ― | 0.37% | -20.49% |
* Healthcare Sector Average
Performance Comparison
MGRM
Monogram Orthopaedics Inc
2.79
0.43
18.22%
ATEC
Alphatec Holdings
10.19
-3.77
-27.01%
APYX
Apyx Medical
1.30
-0.07
-5.11%
ZBH
Zimmer Biomet Holdings
112.26
-16.62
-12.90%
SENS
Senseonics Holdings
0.68
0.16
30.77%
INSP
Inspire Medical Systems
157.24
-52.39
-24.99%
Monogram Orthopaedics Inc Earnings Call Summary
Earnings Call Date: Mar 12, 2025 | % Change Since: 20.26% | Next Earnings Date: May 20, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view of achievements and challenges. While the company has made significant technological advancements and maintains a strong cash position, uncertainties around regulatory approvals and capital needs for product launch temper the positive outlook.Highlights
Strong Cash Position
Ended the year with a cash balance of $15.7 million, higher than the previous year, due to frugal spending and a successful oversubscribed $13 million preferred D raise.
Technological Advancements in Robotic Surgery
Developed an autonomous cutting system that can cut bone with high accuracy and speed, nearly a 300% increase in feed rate, making it competitive with manual surgery.
Regulatory Progress
Successfully responded to the FDA's questions and submitted for regulatory approval in India with ongoing communications.
Lowlights
Regulatory Uncertainties
Awaiting clearance decisions from both the FDA and Indian Regulatory Authority, with timelines and outcomes uncertain.
Capital and Resource Constraints
Acknowledged need for additional capital to support aggressive product launch and sales and marketing efforts post-FDA approval.
Clinical Trial Timeline
Trial in India dependent on hardware and personnel constraints, may take several months to complete enrollment and follow-up.
Company Guidance
During the Monogram Technologies conference call, CFO Noel Knape highlighted key financial metrics, including ending the year with a cash balance of $15.7 million, which was attributed to maintaining a monthly cash burn rate of approximately $1.2 million, a successful oversubscribed $13 million preferred D raise, and strategic investments by senior management. The company has a strong balance sheet and no traditional debt, allowing it to be well-prepared for upcoming milestones. Monogram has 27 full-time employees and uses outsourced engineering talent as needed, with a focus on optimizing cost structure. CEO Benjamin Sexson discussed the company's progress in robotic knee replacement technology, emphasizing the significance of their fully autonomous cutting system and the ongoing regulatory processes in both the U.S. and India. The call also touched on the expected timelines for clinical trials, the anticipated FDA decision, and future capital requirements for scaling operations.Monogram Orthopaedics Inc Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Monogram Orthopaedics Gains FDA Clearance for TKA System
Positive
Mar 17, 2025
On March 17, 2025, Monogram Technologies Inc. announced that it received FDA 510(k) clearance for its Monogram mBôs™ TKA System, allowing it to market the device under specific regulatory provisions. This clearance marks a significant milestone for the company, highlighting years of innovation and teamwork in advancing orthopedic robotics. The system is designed to enhance safety, efficiency, and accuracy in robotic-assisted total knee arthroplasty and is positioned for future expansion into other orthopedic applications. The company is preparing for commercialization and aims to establish clinical experience with key surgeons to demonstrate the system’s advantages. This development opens new domestic and international opportunities, supporting Monogram’s strategic growth and long-term commercialization strategy.
Product-Related AnnouncementsBusiness Operations and StrategyRegulatory Filings and Compliance
Monogram Orthopaedics Awaits FDA Clearance for mBôs TKA System
Positive
Feb 25, 2025
On February 25, 2025, Monogram Technologies Inc. announced the completion of supplemental testing and submission of a formal response to the FDA’s Additional Information Request for its mBôs TKA System. The company anticipates a favorable clearance decision, which would allow commercialization in the U.S. Monogram also held an Investigator Meeting in India as part of a collaboration with Shalby Limited and Reliance Life Sciences to prepare for a clinical trial of the mBôs TKA System. The company has made significant advancements in its robotic system, enhancing cutting speeds and maintaining accuracy, positioning it as a competitive solution in the orthopedic robotics market.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.